Symbols / KALV
KALV Chart
About
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 797.12M |
| Enterprise Value | 770.54M | Income | -203.10M | Sales | 1.43M |
| Book/sh | 0.34 | Cash/sh | 6.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 270 | IPO | — |
| P/E | — | Forward P/E | -10.82 | PEG | — |
| P/S | 558.99 | P/B | 46.93 | P/C | — |
| EV/EBITDA | -3.82 | EV/Sales | 540.35 | Quick Ratio | 5.16 |
| Current Ratio | 5.37 | Debt/Eq | 1662.33 | LT Debt/Eq | — |
| EPS (ttm) | -3.94 | EPS next Y | -1.46 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -60.98% |
| ROE | -190.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -3.36% | Profit Margin | 0.00% | Shs Outstand | 50.55M |
| Shs Float | 27.28M | Short Float | 44.66% | Short Ratio | 15.62 |
| Short Interest | — | 52W High | 19.00 | 52W Low | 9.23 |
| Beta | -0.35 | Avg Volume | 1.15M | Volume | 422.37K |
| Target Price | $34.00 | Recom | Strong_buy | Prev Close | $15.77 |
| Price | $15.77 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$34.00
Mean price target
2. Current target
$15.79
Latest analyst target
3. DCF / Fair value
$-35.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.79
Low
$22.00
High
$39.00
Mean
$34.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-09 | main | HC Wainwright & Co. | Buy → Buy | $37 |
| 2026-01-09 | main | Needham | Buy → Buy | $35 |
| 2026-01-06 | main | Needham | Buy → Buy | $32 |
| 2025-12-04 | reit | Needham | Buy → Buy | $28 |
| 2025-11-11 | main | Citizens | Market Outperform → Market Outperform | $28 |
| 2025-09-12 | reit | Needham | Buy → Buy | $28 |
| 2025-09-12 | main | JMP Securities | Market Outperform → Market Outperform | $28 |
| 2025-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-07-08 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2025-07-08 | main | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-07-07 | main | Leerink Partners | Outperform → Outperform | $20 |
| 2025-04-08 | reit | Needham | Buy → Buy | $28 |
| 2025-03-26 | reit | Needham | Buy → Buy | $28 |
| 2025-03-26 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $19 |
| 2025-03-26 | main | Jones Trading | Buy → Buy | $30 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-03-13 | reit | Needham | Buy → Buy | $28 |
| 2025-03-03 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $19 |
| 2025-01-31 | init | JMP Securities | — → Market Outperform | $19 |
| 2025-01-07 | init | TD Cowen | — → Buy | $30 |
- Investors get two chances to hear KalVista in March webcasts - Stock Titan Wed, 25 Feb 2026 12
- Insider Sale: CHIEF MEDICAL OFFICER of $KALV Sells 5,354 Shares - Quiver Quantitative Wed, 25 Feb 2026 01
- KalVista Pharma chief development officer sells $67,668 in stock - Investing.com Wed, 25 Feb 2026 06
- Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet - Finviz ue, 24 Feb 2026 16
- KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion (KALV) - Seeking Alpha Wed, 11 Feb 2026 08
- KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? - Nasdaq hu, 10 Jul 2025 07
- Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Bausch Health Companies (BHC) and Insulet (PODD) - The Globe and Mail Fri, 20 Feb 2026 13
- EKTERLY study tracks hereditary angioedema attacks at AAAAI 2026 - Stock Titan hu, 12 Feb 2026 08
- KalVista Pharma CCO Sweeny Sold $61,878 in Stock - Investing.com UK Wed, 25 Feb 2026 00
- KALVISTA PHARMACEUTICALS Earnings Preview: Recent $KALV Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative ue, 02 Sep 2025 07
- TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results - Yahoo Finance Mon, 02 Feb 2026 08
- Oral HAE pill lets adolescents treat attacks at first sign - Stock Titan Wed, 18 Feb 2026 12
- Kalvista Pharma CFO Piekos sells $27,506 in shares - Investing.com UK Wed, 25 Feb 2026 04
- $KALV stock is up 18% today. Here's what we see in our data. - Quiver Quantitative Fri, 09 Jan 2026 08
- KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance Mon, 10 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10034 | 156197.0 | — | Sale at price 15.57 per share. | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
| 1 | 4347 | 67669.0 | — | Sale at price 15.57 per share. | YEA CHRISTOPHER M | Officer | — | 2026-02-23 00:00:00 | D |
| 2 | 1767 | 27507.0 | — | Sale at price 15.57 per share. | PIEKOS BRIAN | Chief Financial Officer | — | 2026-02-23 00:00:00 | D |
| 3 | 3975 | 61878.0 | — | Sale at price 15.57 per share. | SWEENY NICOLE | Officer | — | 2026-02-23 00:00:00 | D |
| 4 | 5354 | 83345.0 | — | Sale at price 15.57 per share. | AUDHYA PAUL K | Officer | — | 2026-02-23 00:00:00 | D |
| 5 | 6875 | nan | — | — | YEA CHRISTOPHER M | Officer | — | 2026-02-20 00:00:00 | D |
| 6 | 5000 | nan | — | — | PIEKOS BRIAN | Chief Financial Officer | — | 2026-02-20 00:00:00 | D |
| 7 | 11250 | nan | — | — | SWEENY NICOLE | Officer | — | 2026-02-20 00:00:00 | D |
| 8 | 11250 | nan | — | — | AUDHYA PAUL K | Officer | — | 2026-02-20 00:00:00 | D |
| 9 | 23250 | nan | — | — | PALLEIKO BENJAMIN L | Chief Executive Officer | — | 2026-02-20 00:00:00 | D |
Financials
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 479.22K | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -175.61M | -127.29M | -94.32M | -78.63M |
| TotalUnusualItems | 2.28M | 1.46M | -49.00K | -2.12M |
| TotalUnusualItemsExcludingGoodwill | 2.28M | 1.46M | -49.00K | -2.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -183.44M | -126.64M | -92.91M | -82.34M |
| ReconciledDepreciation | 941.00K | 816.00K | 718.00K | 564.00K |
| EBITDA | -173.33M | -125.83M | -94.37M | -80.75M |
| EBIT | -174.27M | -126.64M | -95.09M | -81.31M |
| NetInterestIncome | 650.00K | 3.90M | 2.23M | 1.09M |
| InterestExpense | 5.79M | 0.00 | ||
| InterestIncome | 6.43M | 3.90M | 2.23M | 1.09M |
| NormalizedIncome | -185.25M | -128.11M | -92.86M | -80.22M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -183.44M | -126.64M | -92.91M | -82.34M |
| TotalExpenses | 182.98M | 131.99M | 95.09M | 81.31M |
| TotalOperatingIncomeAsReported | -188.00M | -140.44M | -110.87M | -96.61M |
| DilutedAverageShares | 49.65M | 36.79M | 27.89M | 24.47M |
| BasicAverageShares | 49.65M | 36.79M | 27.89M | 24.47M |
| DilutedEPS | -3.69 | -3.44 | -3.33 | -3.36 |
| BasicEPS | -3.69 | -3.44 | -3.33 | -3.36 |
| DilutedNIAvailtoComStockholders | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeCommonStockholders | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncome | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeIncludingNoncontrollingInterests | -183.44M | -126.64M | -92.91M | -82.34M |
| NetIncomeContinuousOperations | -183.44M | -126.64M | -92.91M | -82.34M |
| TaxProvision | 3.39M | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -180.05M | -126.64M | -92.91M | -82.34M |
| OtherIncomeExpense | 2.28M | 1.45M | -53.00K | -2.12M |
| OtherNonOperatingIncomeExpenses | -3.00K | -10.00K | -4.00K | -1.00K |
| GainOnSaleOfSecurity | 2.28M | 1.46M | -49.00K | -2.12M |
| NetNonOperatingInterestIncomeExpense | 650.00K | 3.90M | 2.23M | 1.09M |
| InterestExpenseNonOperating | 5.79M | 0.00 | ||
| InterestIncomeNonOperating | 6.43M | 3.90M | 2.23M | 1.09M |
| OperatingIncome | -182.98M | -131.99M | -95.09M | -81.31M |
| OperatingExpense | 182.98M | 131.99M | 95.09M | 81.31M |
| OtherTaxes | -5.01M | -8.45M | -15.79M | -15.30M |
| ResearchAndDevelopment | 71.71M | 86.17M | 80.28M | 70.17M |
| SellingGeneralAndAdministration | 116.29M | 54.28M | 30.59M | 26.45M |
| GeneralAndAdministrativeExpense | 116.29M | 54.28M | 30.59M | 26.45M |
| OtherGandA | 116.29M | 54.28M | 30.59M | 26.45M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-04-30 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 49.76M | 42.52M | 34.17M | 24.55M |
| ShareIssued | 49.76M | 42.52M | 34.17M | 24.55M |
| TotalDebt | 6.31M | 7.32M | 8.23M | 8.19M |
| TangibleBookValue | 95.39M | 206.58M | 161.03M | 185.09M |
| InvestedCapital | 95.39M | 206.58M | 161.03M | 185.09M |
| WorkingCapital | 196.52M | 202.88M | 157.29M | 182.07M |
| NetTangibleAssets | 95.39M | 206.58M | 161.03M | 185.09M |
| CapitalLeaseObligations | 6.31M | 7.32M | 8.23M | 8.19M |
| CommonStockEquity | 95.39M | 206.58M | 161.03M | 185.09M |
| TotalCapitalization | 95.39M | 206.58M | 161.03M | 185.09M |
| TotalEquityGrossMinorityInterest | 95.39M | 206.58M | 161.03M | 185.09M |
| StockholdersEquity | 95.39M | 206.58M | 161.03M | 185.09M |
| GainsLossesNotAffectingRetainedEarnings | -5.21M | -3.49M | -3.06M | -3.86M |
| OtherEquityAdjustments | -5.21M | -3.49M | -3.06M | |
| RetainedEarnings | -653.17M | -469.73M | -343.08M | -250.18M |
| AdditionalPaidInCapital | 753.73M | 679.75M | 507.13M | 439.10M |
| CapitalStock | 50.00K | 42.00K | 34.00K | 25.00K |
| CommonStock | 50.00K | 42.00K | 34.00K | 25.00K |
| TotalLiabilitiesNetMinorityInterest | 155.38M | 28.82M | 22.18M | 18.79M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 110.21M | 6.01M | 7.14M | 7.21M |
| NonCurrentDeferredLiabilities | 105.88M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 4.33M | 6.01M | 7.14M | 7.21M |
| LongTermCapitalLeaseObligation | 4.33M | 6.01M | 7.14M | 7.21M |
| CurrentLiabilities | 45.17M | 22.81M | 15.03M | 11.58M |
| CurrentDeferredLiabilities | 11.00M | 0.00 | ||
| CurrentDeferredRevenue | 11.00M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 1.98M | 1.30M | 1.09M | 977.00K |
| CurrentCapitalLeaseObligation | 1.98M | 1.30M | 1.09M | 977.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 16.12M | 6.69M | 4.21M | 4.17M |
| PayablesAndAccruedExpenses | 16.07M | 14.82M | 9.74M | 6.43M |
| CurrentAccruedExpenses | 11.18M | 5.71M | 4.92M | 2.79M |
| Payables | 4.88M | 9.11M | 4.82M | 3.64M |
| AccountsPayable | 4.88M | 9.11M | 4.82M | 3.64M |
| TotalAssets | 250.77M | 235.40M | 183.20M | 203.88M |
| TotalNonCurrentAssets | 9.08M | 9.71M | 10.88M | 10.23M |
| OtherNonCurrentAssets | 1.55M | 567.00K | 106.00K | 193.00K |
| NetPPE | 7.53M | 9.15M | 10.77M | 10.04M |
| AccumulatedDepreciation | -4.75M | -3.71M | -2.96M | -2.42M |
| GrossPPE | 12.28M | 12.86M | 13.73M | 12.46M |
| Leases | 3.09M | 2.86M | 2.85M | 2.00M |
| OtherProperties | 8.20M | 9.33M | 10.23M | 10.02M |
| MachineryFurnitureEquipment | 984.00K | 671.00K | 647.00K | 447.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 241.69M | 225.69M | 172.33M | 193.65M |
| OtherCurrentAssets | 4.92M | |||
| PrepaidAssets | 5.93M | 4.42M | 4.31M | 10.64M |
| Receivables | 15.14M | 10.87M | 18.64M | 16.81M |
| OtherReceivables | 11.00M | |||
| TaxesReceivable | 2.31M | 9.46M | 17.99M | 15.92M |
| AccruedInterestReceivable | 1.83M | 1.41M | 654.00K | 888.00K |
| CashCashEquivalentsAndShortTermInvestments | 220.62M | 210.40M | 149.38M | 166.20M |
| OtherShortTermInvestments | 89.00M | 178.61M | 93.14M | 135.47M |
| CashAndCashEquivalents | 131.62M | 31.79M | 56.24M | 30.73M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| FreeCashFlow | -153.84M | -89.67M | -76.46M | -79.06M |
| RepaymentOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 55.91M | 96.94M | 56.58M | 0.00 |
| CapitalExpenditure | -929.00K | -443.00K | -1.20M | -931.00K |
| EndCashPosition | 132.27M | 31.79M | 56.24M | 30.73M |
| BeginningCashPosition | 31.79M | 56.24M | 30.73M | 50.59M |
| EffectOfExchangeRateChanges | 2.64M | -1.21M | 1.24M | -1.17M |
| ChangesInCash | 97.84M | -23.24M | 24.27M | -18.69M |
| FinancingCashFlow | 159.73M | 150.71M | 58.12M | 1.58M |
| CashFlowFromContinuingFinancingActivities | 159.73M | 150.71M | 58.12M | 1.58M |
| NetOtherFinancingCharges | 98.04M | |||
| ProceedsFromStockOptionExercised | 5.78M | 53.77M | 1.53M | 1.58M |
| NetCommonStockIssuance | 55.91M | 96.94M | 56.58M | 0.00 |
| CommonStockIssuance | 55.91M | 96.94M | 56.58M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | ||
| LongTermDebtPayments | 0.00 | 0.00 | ||
| InvestingCashFlow | 91.02M | -84.72M | 41.41M | 57.86M |
| CashFlowFromContinuingInvestingActivities | 91.02M | -84.72M | 41.41M | 57.86M |
| NetInvestmentPurchaseAndSale | 91.95M | -84.28M | 42.61M | 58.79M |
| SaleOfInvestment | 122.52M | 104.95M | 140.86M | 195.71M |
| PurchaseOfInvestment | -30.57M | -189.23M | -98.25M | -136.92M |
| NetPPEPurchaseAndSale | -434.00K | -42.00K | -1.20M | -931.00K |
| PurchaseOfPPE | -434.00K | -42.00K | -1.20M | -931.00K |
| CapitalExpenditureReported | -495.00K | -401.00K | 0.00 | 0.00 |
| OperatingCashFlow | -152.91M | -89.23M | -75.26M | -78.13M |
| CashFlowFromContinuingOperatingActivities | -152.91M | -89.23M | -75.26M | -78.13M |
| ChangeInWorkingCapital | 15.04M | 15.17M | 7.41M | -12.32M |
| ChangeInOtherWorkingCapital | 10.56M | |||
| ChangeInOtherCurrentAssets | -22.00K | |||
| ChangeInPayablesAndAccruedExpense | 9.46M | 7.53M | 3.04M | 2.16M |
| ChangeInAccruedExpense | 14.43M | 3.21M | 1.93M | 472.00K |
| ChangeInPayable | -4.97M | 4.32M | 1.11M | 1.69M |
| ChangeInAccountPayable | -4.97M | 4.32M | 1.11M | 1.69M |
| ChangeInPrepaidAssets | -1.36M | -538.00K | 6.69M | -9.28M |
| ChangeInReceivables | -3.62M | 8.18M | -2.32M | -5.20M |
| OtherNonCashItems | 6.24M | -12.00K | 84.00K | 179.00K |
| StockBasedCompensation | 12.29M | 21.91M | 9.92M | 11.09M |
| AmortizationOfSecurities | 14.00K | 92.00K | 988.00K | 2.56M |
| DepreciationAmortizationDepletion | 941.00K | 816.00K | 718.00K | 564.00K |
| DepreciationAndAmortization | 941.00K | 816.00K | 718.00K | 564.00K |
| OperatingGainsLosses | -3.99M | -565.00K | -1.48M | 2.13M |
| GainLossOnInvestmentSecurities | 189.00K | -1.32M | 139.00K | 581.00K |
| NetForeignCurrencyExchangeGainLoss | -4.17M | 760.00K | -1.62M | 1.55M |
| NetIncomeFromContinuingOperations | -183.44M | -126.64M | -92.91M | -82.34M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KALV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|